Thrombocytosis is usually discovered incidentally, but the differential diagnosis is important.
In cases of reactive, or secondary, thrombocytosis, the underlying disease may require …

Glucose-6-phosphate dehydrogenase deficiency serves as a prototype of the many human
enzyme deficiencies that are now known. Since its discovery more than 50 years ago, the …

Background Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are
clonal myeloproliferative disorders arising from a multipotent progenitor. The loss of …

Abstract Interferon-α (IFN-α) is a nonleukemogenic treatment of polycythemia vera (PV) able
to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment …

Pegylated interferon α-2a (PEG-IFN-α-2a) has previously been shown to induce
hematologic and molecular responses in patients with polycythemia vera (PV) or essential …

An acquired somatic mutation, Jak2 V617F, was recently discovered in most patients with
polycythemia vera (PV), chronic idiopathic myelofibrosis (CIMF), and essential …

To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27
patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid …

Interferon alpha (IFN-α) has been used for over 30 years to treat myeloproliferative
neoplasms (MPNs). IFN-α was shown to induce clinical, hematological, molecular and …

IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy
is likely the consequence of its broad range of biologic activities, including direct effects on …

The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often
problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd …